In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Aerie Pharma (AERI), with a price target of $77. The company’s shares opened today at $42.85.
Yang observed:
“We are including weekly IQVIA Scripts for Rhopressa below. In the week ended 01/11/2019, Rhopressa TRx increased by +14%, while Rhopressa NRx increased by +30%.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 15.3% and a 44.9% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Xeris Pharmaceuticals Inc, and Alder Biopharmaceuticals.
Aerie Pharma has an analyst consensus of Strong Buy, with a price target consensus of $82, implying a 91.4% upside from current levels. In a report issued on January 4, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $86 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $74.75 and a one-year low of $32.18. Currently, Aerie Pharma has an average volume of 581.7K.
Based on the recent corporate insider activity of 40 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AERI in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aerie Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of therapies for the treatment of patients with glaucoma and diseases of the eye. Its products include Rhopressa and Roclatan.
